Alan Barge
- Hematology top 1%
- Acute Myeloid Leukemia Research 6
- Hematopoietic Stem Cell Transplantation 4
- Platelet Disorders and Treatments 3
- Oncology top 5%
- Cancer Treatment and Pharmacology 6
- Neutropenia and Cancer Infections 4
- Colorectal Cancer Treatments and Studies 2
- Genetics top 5%
- Cancer Research top 10%
- Pathology and Forensic Medicine top 10%
-
- Angiogenesis and VEGF in Cancer 5
- PI3K/AKT/mTOR signaling in cancer 3
- Co-authors
- Catherine WheelerM. BoogaertsAugustin FerrantDavid C. LinchH DemuynckPeter DregerHartmut LinkNorbert Schmitz
- Cited by
- HematologyOncologyGenetics
- Partner nations
- United KingdomGermanyUnited States
In The Last Decade
Alan Barge
20 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 84
- Hematology 664
- Oncology 819
- Genetics 183
- Cancer Research 166
- Pathology and Forensic Medicine 179
Countries citing papers authored by Alan Barge
This map shows the geographic impact of Alan Barge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Barge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Barge more than expected).
Fields of papers citing papers by Alan Barge
This network shows the impact of papers produced by Alan Barge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Barge. The network helps show where Alan Barge may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Alan Barge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 27 | |
| 2 | 2018 | 23 | |
| 3 | 2014 | 2 | |
| 4 | 2008 | 54 | |
| 5 | 2007 | 25 | |
| 6 | 2006 | 19 | |
| 7 | 2006 | 31 | |
| 8 | Pharmacodynamic assessment of ZD6474 (ZACTIMA (TM)) in the skin of patients with previously treated metastatic breast cancer. | 2005 | 1 |
| 9 | 2005 | 247 | |
| 10 | 2005 | 15 | |
| 11 | 2005 | 155 | |
| 12 | [Comparison of management of advanced cancer in various organs]. | 2001 | 0 |
| 13 | 1999 | 83 | |
| 14 | 1999 | 4 | |
| 15 | 1998 | 13 | |
| 16 | 1997 | 11 | |
| 17 | 1997 | 231 | |
| 18 | 1996 | 462 | |
| 19 | Results of a randomised, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia | 1995 | 12 |
| 20 | [The ABO system and transplantation. Effect of pre-immunization with soluble A substance]. | 1967 | 5 |
About Alan Barge
Alan Barge is a scholar working on Hematology, Oncology and Hepatology, having authored 21 papers that have together received 1.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (6 papers), Cancer Treatment and Pharmacology (6 papers), Angiogenesis and VEGF in Cancer (5 papers), Neutropenia and Cancer Infections (4 papers), Hematopoietic Stem Cell Transplantation (4 papers), Platelet Disorders and Treatments (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Hematology (664 citations), Oncology (819 citations) and Genetics (183 citations). Alan Barge has collaborated with scholars based in United Kingdom, Germany and United States. Frequent co-authors include Catherine Wheeler, M. Boogaerts, Augustin Ferrant, David C. Linch, H Demuynck, Peter Dreger, Hartmut Link, Norbert Schmitz, Keith M. Borkett and A. H. Goldstone. Their work appears in journals such as Blood, Clinical Cancer Research, Investigational New Drugs, Contemporary Clinical Trials and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.